GW Pharmaceuticals plc (NASDAQ:GWPH) traded 3.34 Million shares on last trading day with closing price of $126.06. Company gross margin stands at 81.60% whereas its return on investment (ROI) is -18.10%. Stock value has moved between $35.81 – 111.56 in last one year. Analyst’s mean target price for GW Pharmaceuticals plc (NASDAQ:GWPH) while analysts mean […]

by

NEW YORK, September 27, 2016 /PRNewswire/ — Despite all the advances we have made in the medical field, overcoming addictions are still a challenge with an unmet need. Nicotine remains the largest addiction problem in the world. Consumers seem to be somewhat shifting from the traditional tobacco cigarettes to smokeless tobacco. According to a research […]

by

Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo Today’s data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016 Data reinforce the potential of Epidiolex to be an important new medicine for patients who suffer from this treatment-resistant childhood-onset epilepsy Company to hold investor conference […]

by

– Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo –  – Today’s data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016 – – Data reinforce the potential of Epidiolex to be an important new medicine for patients who suffer from this treatment-resistant childhood-onset epilepsy […]

by

Epidiolex is an orphan drug that is pharmaceutical cannabidiol, not medical marijuana. The drug helps treat various types of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. GW Pharma’s study revealed that patients taking 20 mg of Epidiolex had a medium reduction in monthly seizures of 42 percent versus a 17 percent reduction for those […]

by

Pfizer Inc. (NYSE:PFE) traded 12.94 Million shares on last trading day with closing price of $34.26. Company gross margin stands at 77.80% whereas its return on investment (ROI) is 7.30%. Stock value has moved between $27.85 – 37.24 in last one year. Analyst’s mean target price for Pfizer Inc. (NYSE:PFE) is $39.47 while analysts mean […]

by

– Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo –  – Today’s data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016 – – Data reinforce the potential of Epidiolex to be an important new medicine for patients who suffer from this treatment-resistant childhood-onset epilepsy […]

by

DEVON, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated a Phase 2 clinical trial, STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis (OA)), of ZYN002 cannabidiol […]

by

PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of […]

by

Lord says that for those children who can and want to type, it can be beneficial. But there’s no guarantee that all children with autism can learn to type. “There are a very small number of people with autism who you’d think could never type, who do become able to type independently,” Lord says. Today, […]

by